Table 1.
Patients Donors and Transplants characteristics.
| ATLG Dose | 15 mg/Kg | 30 mg/Kg | P |
|---|---|---|---|
| N (%) | N (%) | ||
| Total Patients | 71 (100) | 94 (100) | |
| Patient age median (range) | 57 (20–72) | 58 (20–71) | 0.88 |
| ≤58 Years | 40 (56) | 49 (52) | 0.6 |
| >58 Years | 31 (44) | 45 (48) | |
| Disease | <0.001 | ||
| Acute Leukemia | 39 (55) | 30 (32) | |
| ALL | 0 (0) | 1 (1) | |
| AML | 39 (55) | 29 (31) | |
| MDS/MPN | 26 (37) | 19 (20) | |
| CML | 1 (1) | 3 (3) | |
| MDS | 18 (25) | 14 (15) | |
| MDS/MPN | 7 (10) | 2 (2) | |
| Others | 39 (55) | 30 (32) | |
| MM | 0 (0) | 4 (4) | |
| NHL | 6 (9) | 6 (6) | |
| Histiocytosis | 0 (0) | 1 (0.01) | |
| PMF | 0 (0) | 34 (36) | |
| DRSS | <0.0001 | ||
| Standard | 7 (10) | 12 (13) | |
| Intermediate 1 | 25 (35) | 18 (19) | |
| Intermediate 2 | 11 (16) | 46 (50) | |
| High | 16 (23) | 4 (4) | |
| Very High | 12 (17) | 13 (14) | |
| Unknown | 0 (0) | 1 (0.1) | |
| ECOG | |||
| 0 | 13 (18) | 34 (36) | 0.001 |
| 1 | 51 (72) | 60 (64) | |
| 2 | 7 (9) | 0 (0) | |
| KI at SCT median (range) | 80 (50–100) | 80 (80–100) | 0.001 |
| Donor Age median (range) | 57 (28–70) | 58 (18–79) | 0.5 |
| ≤57 Years | 41 (58) | 47 (50) | 0.32 |
| >57 Years | 30 (42) | 47 (50) | |
| Recipient/Donor CMV Serology | |||
| -/- | 14 (20) | 26 (28) | 0.44 |
| -/+ | 10 (14) | 17 (18) | |
| +/+ | 31 (44) | 31 (33) | |
| +/- | 16 (23) | 20 (21) | |
| Recipient-Donor sex | 0.17 | ||
| MM | 20 (28) | 32 (34) | |
| MF | 21 (30) | 25 (27) | |
| FF | 11 (16) | 23 (25) | |
| FM | 19 (27) | 14 (15) | |
| ABO incompatibility | |||
| Isogroup | 50 (70) | 71 (76) | 0.16 |
| Minor | 9 (13) | 6 (6) | |
| Major | 12 (17) | 13 (14) | |
| Bidirectional | 0 (0) | 4 (4) | |
| Allo-SCT Year | 2020 (2018–2022) | 2018 (2011–2022) | <0.001 |
| ≤ 2019 | 35 (49) | 83 (88) | <0.001 |
| > 2019 | 36 (51) | 11 (12) | |
| CD34x106/kg median (range) | 5.1 (2.5–11.7) | 5.8 (1.9–11.2) | 0.02 |
| ≤5.7 ×106/kg | 43 (61) | 39 (43) | 0.025 |
| >5.7 ×106/kg | 28 (39) | 52 (57) | |
| Conditioning intensity | |||
| MAC | 48 (68) | 45 (48) | 0.011 |
| RIC | 23 (32) | 49 (52) | |
| TBI | 9 (13) | 5 (5) | 0.09 |
| 2 Gy | 0 (0) | 1 (20) | |
| 8 Gy | 8 (89) | 0 (0) | |
| 9 Gy | 0(0) | 1 (20) | |
| 12 Gy | 1 (11) | 3 (60) | |
| Conditioning Regimen | <0.001 | ||
| Bu-Cy | 0 (0) | 6 (6) | |
| Bu-Flu | 17 (24) | 55 (59) | |
| Bu-Flu-other | 0 (0) | 2 (2) | |
| Bu-TT | 27 (38) | 1 (1) | |
| FLAMSA-BuFlu | 4 (6) | 11 (12) | |
| FLAMSA-other | 0 (0) | 1 (1) | |
| FLAMSA-Treo | 1 (1) | 0 (0) | |
| Flu-Mel | 0 (0) | 2 (2) | |
| LEAM | 0 (0) | 1 (1) | |
| other | 0 (0) | 2 (2) | |
| TBI-Cy | 0 (0) | 1 (1) | |
| TBI-Flu | 9 (13) | 1 (1) | |
| TBI-Vp | 0 (0) | 1 (1) | |
| TMI-BuCy | 0 (0) | 1 (1) | |
| Treo-Flu | 11 (15) | 9 (10) | |
| Treo-FluTT | 1 (1) | 0 (0) | |
| Treo-TT | 1 (1) | 0 (0) | |
| Immune suppression | 0.73 | ||
| CSA + MMF | 66 (93) | 90 (96) | |
| Tac+MMF | 4 (6) | 3 (3) | |
| other | 1 (1) | 1 (1) | |
| Disease status at SCT | 0.06 | ||
| CR | 31 (44) | 24 (26) | |
| CR1 | 28 (90) | 22 (92) | |
| CR2 | 3 (10) | 2 (8) | |
| PR | 4 (6) | 12 (13) | |
| Progression | 16 (23) | 18 (19) | |
| Relapse | 4 (6) | 3 (3) | |
| PD | 2 (3) | 4 (4) | |
| Primary refractory | 9 (13) | 10 (11) | |
| Rel Refractory | 1 (1) | 1 (1) | |
| Untreated | 20 (28) | 39 (42) | |
| Unknown | 0 (0) | 1 (1) | |
Red: p < 0.05.
ATLG anti-T-lymphocyte globulin, ALL acute lymphoblastic leukemia, AML acute myeloid leukemia, MDS myelodysplastic syndrome, MPN myeloproliferative neoplasm, CML chronic myeloid leukemia, MM multiple myeloma, NHL non-Hodgkin’s lymphoma, PMF primary myelofibrosis, ECOG Eastern Cooperative Oncology Group Performance Status, KI Karnofsky Index (Performance Status), SCT stem cell transplant, CMV cytomegalovirus, ABO ABO Blood Group, MAC myeloablative conditioning, RIC Reduced-Intensity Conditioning, TBI Total Body Irradiation, Bu Busulfan, Cy Cyclophosphamide, Flu Fludarabine, Mel Melphalan, Treo Treosulfan, TT Thiotepa, CSA Ciclosporine, MMF Mycophenolate Mofetil, Tac Tacrolimus, CR Complete Remission, CR1 First Complete Remission, CR2 Second Complete Remission, PR Partial Remission, PD Progressive Disease, Rel Relapse, Rel Refractory: Refractory Relapse, LEAM Lomustine–Etoposide–Ara-C–Melphalan, TMI Total Marrow Irradiation, Vp Etoposide, Allo-SCT Allogeneic Stem Cell Transplant, N Number of patients, % Percentage, p p value.